1. Clinical & Scientific Overview
Cefpodoxime Proxetil (TIP-MED-000134, Reference Code [8.6]) is classified under
Antimicrobials — Antibacterial & Antibiotic Agents (Ch 08) as a Third-Generation Oral Cephalosporin Beta-Lactam Antibiotic (Ester Prodrug; WHO 'Watch' Group).
Within the Indian regulatory and compendial framework, it is governed under Schedule H1 Prescription Drug (Mandatory Red-Bordered Rx Warning & 3-Year Register under Rule 65 of Drugs Rules 1945).
Representative Indian Market Examples (Edition 2.7 Ch 08 [8.6], p. 95): Monocef-O (Aristo), Cepodem (Sun Pharma), Gudcef (Mankind), Swich (Alkem), Doxcef (Lupin) — Strengths & Dosage Forms: Oral Film-Coated / Dispersible Tablets: 100 mg, 200 mg; Paediatric Dry Syrup: 50 mg/5 mL, 100 mg/5 mL
Oral Film-Coated / Dispersible Tablets: 100 mg, 200 mg; Paediatric Dry Syrup: 50 mg/5 mL, 100 mg/5 mL
3. Mechanism of Action & Pharmacodynamics
Third-Generation Oral Cephalosporin Beta-Lactam Antibiotic (Ester Prodrug; WHO 'Watch' Group) acting on target receptor/enzyme pathways in Antimicrobials — Antibacterial & Antibiotic Agents (Ch 08): clinical efficacy is mediated via Third-Generation Oral Cephalosporin Beta-Lactam Antibiotic (Ester Prodrug; WHO 'Watch' Group) for Community-acquired pneumonia, acute bacterial exacerbation of chronic bronchitis, acute maxillary sinusitis, pharyngitis/tonsillitis, acute uncomplicated urinary tract infections, and uncomplicated skin/soft-tissue infections (has better Gram-positive Streptococcal/MSSA activity than cefixime)..
4. Therapeutic Indications & Evidence-Supported Uses
- Community-acquired pneumonia, acute bacterial exacerbation of chronic bronchitis, acute maxillary sinusitis, pharyngitis/tonsillitis, acute uncomplicated urinary tract infections, and uncomplicated skin/soft-tissue infections (has better Gram-positive Streptococcal/MSSA activity than cefixime)
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: General Adult Reference: 100 mg to 200 mg twice daily (every 12 hours) for 5 to 10 days (100 mg BD for uncomplicated UTI/pharyngitis; 200 mg BD for pneumonia, sinusitis, or skin infections). Follow physician prescription.
Administration & Meal Timing: MUST be taken WITH FOOD! (Like cefuroxime axetil, cefpodoxime proxetil requires food and normal gastric acid for optimal ester absorption—taking with meals increases bioavailability from ~40% to >50%). | Twice daily (every 12 hours, with breakfast and dinner).
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Renal: Strictly renal-function dependent! • CrCl ≥30 mL/min: Standard 12-hourly dosing. • CrCl 10–29 mL/min: Extend dosing interval to once every 24 hours (100–200 mg OD). • CrCl <10 mL/min: Administer 3 times a week (after haemodialysis). Hepatic: No dose adjustment needed in cirrhosis.
Renal: Strictly renal-function dependent! • CrCl ≥30 mL/min: Standard 12-hourly dosing. • CrCl 10–29 mL/min: Extend dosing interval to once every 24 hours (100–200 mg OD). • CrCl <10 mL/min: Administer 3 times a week (after haemodialysis). Hepatic: No dose adjustment needed in cirrhosis.
Renal: Strictly renal-function dependent! • CrCl ≥30 mL/min: Standard 12-hourly dosing. • CrCl 10–29 mL/min: Extend dosing interval to once every 24 hours (100–200 mg OD). • CrCl <10 mL/min: Administer 3 times a week (after haemodialysis). Hepatic: No dose adjustment needed in cirrhosis.
7. Contraindications, Precautions & High-Risk Warnings
- Contraindicated in cephalosporin or severe immediate penicillin allergy.
Key Clinical Precautions: Renal: Strictly renal-function dependent! • CrCl ≥30 mL/min: Standard 12-hourly dosing. • CrCl 10–29 mL/min: Extend dosing interval to once every 24 hours (100–200 mg OD). • CrCl <10 mL/min: Administer 3 times a week (after haemodialysis). Hepatic: No dose adjustment needed in cirrhosis.
8. Adverse Effects Profile
- Diarrhoea, loose stools, nausea, abdominal pain, headache, vulvovaginal candidiasis.
- Anaphylaxis, C. difficile colitis, SJS/TEN, reversible leukopenia/thrombocytopenia, neurotoxicity in severe renal failure.
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Antacids (Al/Mg hydroxide), Famotidine, and PPIs reduce oral absorption of cefpodoxime by 30–40% by raising gastric pH—space antacids/H2 blockers at least 2 hours after cefpodoxime and take cefpodoxime with meals
- Potentiates Warfarin INR
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: Always take Monocef-O / Gudcef with breakfast and dinner, never on an empty stomach or simultaneously with an antacid syrup. Complete the full 5-to-7 day course.
- Meal & Clock Timing Instruction: MUST be taken WITH FOOD! (Like cefuroxime axetil, cefpodoxime proxetil requires food and normal gastric acid for optimal ester absorption—taking with meals increases bioavailability from ~40% to >50%). (Twice daily (every 12 hours, with breakfast and dinner).)
- Missed Dose Protocol: Take with food as soon as remembered; maintain 12-hour interval.
- Geriatric Dispensing Pearl: Verify CrCl in elderly patients (>75 years); if CrCl <30 mL/min, reduce frequency from twice daily to once daily.
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Oral Film-Coated / Dispersible Tablets: 100 mg, 200 mg; Paediatric Dry Syrup: 50 mg/5 mL, 100 mg/5 mL
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 08 [8.6] (p. 95)
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [8.21] Clindamycin Hydrochloride / Phosphate — Lincosamide 50S Ribosomal Inhibitor & Bacterial Toxin Suppressor
- [8.22] Linezolid — Oxazolidinone 50S Ribosomal Initiation Complex Inhibitor — ICMR '
- [8.23] Amikacin Sulfate & Gentamicin Sulfate — Aminoglycoside 30S Ribosomal Bactericidal Antibiotics (Schedule H
- [8.24] Moxifloxacin & Ofloxacin — Fourth- & Second-Generation Fluoroquinolone DNA Gyrase / Topoisom